On August 4, 2022, the U.S. Department of Health and Human Services (HHS) declared a public health emergency (PHE) in response to the current monkeypox outbreak.
CMS has published a new proposed rule intended to strengthen access to emergency care and additional outpatient services in rural communities by establishing the Conditions of Participation (CoP) for Rural Emergency Hospitals (REHs).
The National Independent Laboratory Association (NILA) applauds a bipartisan, bicameral group of legislators for working together to introduce the Saving Access to Laboratory Services Act (SALSA) to protect community and regional independent laboratories from drastic cuts to reimbursement in 2023 and future years. Learn More
The U.S. Centers for Disease Control and Prevention (CDC) will host a virtual biosafety town hall on medical device design in collaboration with clinical and public health laboratory partners and instrument manufacturers on June 24, 2022, from 10:00 AM to 3:30 PM EDT. Learn More
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Laboratory Corporation of America (Labcorp) VirSeq SARS-CoV-2 NGS Test on the PacBio Sequel II sequencing system. Learn More
On June 6, 2022, CDC published a Real-Time PCR test procedure to detect Monkeypox virus. Learn More
NILA has joined with eight parties to a new CDC Memorandum of Understanding (MOU) for Diagnostic Surge Testing Capacity for Public Health Emergencies (PHEs). Parties to the MOU agree to collaborate on enhancing laboratory testing surge capacity outside of CDC and public health laboratories before and during PHEs. Learn More
On May 21, 2022, NILA submitted comments to Senator Patty Murray, chair of the Senate Committee on Health, Education, Labor & Pensions (HELP) and Senator Richard Burr, ranking member of the HELP Committee, on the discussion draft of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022. Learn More
NILA has signed a letter, along with 66 other health care organizations, to House and Senate leaders (Senators Schumer and McConnell and House members Pelosi and McCarthy) requesting Congress to restore funding for COVID-19 testing under the HRSA program. Learn More
NILA has prepared background information and template letters for you to use to communicate to your Members of Congress the potentially severe disruptions in the Nation?s COVID response if funding for COVID-19 testing for uninsured patients is allowed to run out. Learn More
Thank you to everyone who participated in and supported NILA?s Lab Leaders Forum and Mid-Year Meeting. Our return to an in-person meeting was a great success, and we look forward to seeing you again soon! Learn More
Antibodies are developed by the body in response to an infection or after vaccination. SARS-CoV-2 is the virus that causes COVID-19. SARS-CoV-2 antibody tests detect antibodies to the SARS-CoV-2 virus. Learn More
Click here to see NILA's archived news.